19 4月 2021 by admin in UncategorizedComments Citrine Medicine and Sinopharm Group Announce Strategic Partnership to Broaden and Accelerate Access to Rare Disease Drugs in China
16 4月 2021 by admin in UncategorizedComments New data demonstrate that Humabodies® are highly effective in generating monospecific and bispecific CAR-T cells to target solid tumours
13 4月 2021 by admin in UncategorizedComments Arcellx Closes $115 Million Series C Financing to Advance its Pipeline of Adaptive and Controllable Cell Therapies
13 4月 2021 by admin in UncategorizedComments Adicet Bio Appoints Dr. Blake Aftab as Vice President of Research
10 4月 2021 by admin in UncategorizedComments NextCure Presents Preclinical Data for NC762 at American Association for Cancer Research (AACR)
06 4月 2021 by admin in UncategorizedComments Arcellx Announces FDA Clearance of IND Application for ACLX-001, a Controllable Cell Therapy Utilizing the Company’s ARC-SparX Platform, for the Treatment of Multiple Myeloma
30 3月 2021 by admin in UncategorizedComments Design Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters
